Non-compliance, requests for generics on the rise, says survey

Share this article:
Physicians say patient compliance is getting worse, and they're hearing more requests for generic or OTC alternatives to prescribed medications as the economic malaise takes its toll, according to a Pri-Med survey.

Of the 473 respondents, 70% said they are hearing patients increasingly request generic or OTC alternatives, and 68% said they've noticed an increase in non-compliant behaviors with regards to medication usage among patients. More than half said they're seeing changes in patient payment, such as increased delinquencies or requests for payment plans, and 88% are seeing changes to patients' appointment behaviors, including increased cancellations and refusals of tests or screening procedures.

As a result, clinicians reported spending more time with patients at the point of care discussing prescription alternatives or the importance of compliance and prevention. They're also devoting more time to investigating lower-cost treatment options and formulary specifics to help out their patients, and more than three-quarters said they're making changes to their practice such as taking steps to minimize cancellations, expanding payment options and offering online or phone-based consultations.

The web-based poll, conducted from May 14 to May 21, was emailed to more than 16,000 Pri-Med alumni clinicians and garnered a response rate of 3%, the company said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...